In January 1897, attorney P.H. Nelson left his position as solicitor of the Fifth Judicial Circuit to set up a private law practice in Columbia, S.C. The State newspaper contained a short but prescient news item on Jan. 26 about the endeavor, which noted that "the new firm should meet with great success."
And they were right. Today, Nelson Mullins Riley & Scarborough LLP offers legal services in 15 states and the District of Columbia from 31 offices with 930+ attorneys, policy advisors, and professionals. It is the 71st largest law firm in the nation based on 2020 gross revenues, according to The American Lawyer’s Am Law 100, a legal news organization that tracks law firm growth.
Throughout 2022, Nelson Mullins will be sharing seminal events from its history that highlight its growth from a one-man firm in 1897 to where we are today. Click here to learn more.
May 6, 2022
New data published by the Centers for Disease Control and Prevention (“CDC”) indicates that the divide between rural and urban areas in COVID-19 primary vaccination coverage has more than doubled in under a year.
Vaccine Hesitancy and the Growing Divideour team can guide you each step of the way.
Our team brings you real world, practical perspectives and includes
Our clients span industry sectors and are both large and small, ranging from entrepreneurs and start-ups to established household names. Clients we've served include medical and research institutions, global specialty chemical companies, U.S. financial institutions, and clients in a range of business areas, including
Clients who do business on a worldwide basis have entrusted us to maintain a large portfolio of domestic and international patent application filings. In addition to our work representing clients across the United States and around the globe, we bring to you a network of patent legal contacts around the world. Nelson Mullins also brings to you an IP legal team with experience representing clients in transactional proceedings and in IP litigation in the United States, Europe, Asia, and South America.
Our experience in the area of antibody-based therapeutics and related platform technologies includes providing client services to over 30 leading companies in the field. More particular experience areas include: Antibody formats (Humanized, chimeric and fully human antibodies, Alternative scaffolds, Glycoforms, Antibody drug conjugates, Bispecific and multispecific formats), Antisense and RNAi, Discovery technologies (Phage and yeast display, Affinity maturation, Acellular expression, Transgenic production), FDA labelling/clinical trials, Gene Therapy, Green technologies, Metabolites, Nutraceuticals, Personalized medicine/ biomarkers, Prodrugs, Recombinant proteins, Salts/polymorphic crystal forms, Sequencing technologies, and Small molecules.
Following is a selected sampling of matters and is provided for informational purposes only. Past success does not indicate the likelihood of success in any future matter.
Our team brings you real world, practical perspectives and includes
Our clients span industry sectors and are both large and small, ranging from entrepreneurs and start-ups to established household names. Clients we've served include medical and research institutions, global specialty chemical companies, U.S. financial institutions, and clients in a range of business areas, including
Clients who do business on a worldwide basis have entrusted us to maintain a large portfolio of domestic and international patent application filings. In addition to our work representing clients across the United States and around the globe, we bring to you a network of patent legal contacts around the world. Nelson Mullins also brings to you an IP legal team with experience representing clients in transactional proceedings and in IP litigation in the United States, Europe, Asia, and South America.
Our experience in the area of antibody-based therapeutics and related platform technologies includes providing client services to over 30 leading companies in the field. More particular experience areas include: Antibody formats (Humanized, chimeric and fully human antibodies, Alternative scaffolds, Glycoforms, Antibody drug conjugates, Bispecific and multispecific formats), Antisense and RNAi, Discovery technologies (Phage and yeast display, Affinity maturation, Acellular expression, Transgenic production), FDA labelling/clinical trials, Gene Therapy, Green technologies, Metabolites, Nutraceuticals, Personalized medicine/ biomarkers, Prodrugs, Recombinant proteins, Salts/polymorphic crystal forms, Sequencing technologies, and Small molecules.
Following is a selected sampling of matters and is provided for informational purposes only. Past success does not indicate the likelihood of success in any future matter.
We use cookies to improve functionality and performance of our website and to provide you with the best possible browsing experience. These cookies include those which are strictly necessary for website operation, as well as those which are used for functionality and performance purposes.
For more information on how our Sites use cookies, click here to view our Cookie Policy.